Welcome to our dedicated page for Vir Biotechnology news (Ticker: $VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vir Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vir Biotechnology's position in the market.
Vir Biotechnology provided a corporate update and reported financial results for the first quarter of 2024. They announced the acceptance of late-breaker SOLSTICE data abstract for poster presentation at the EASL Congress 2024, with two additional hepatitis program data readouts on track for the fourth quarter. The company had $1.51 billion in cash, cash equivalents, and investments as of March 31, 2024. Key pipeline programs include Chronic Hepatitis Delta and Chronic Hepatitis B, with abstracts accepted for poster presentation at the EASL Congress 2024. Additionally, the Company is advancing next-generation antibodies using its proprietary platform and expects to file multiple investigational new drug applications within the next 18 months.
Vir Biotechnology, Inc. (Nasdaq: VIR) CEO Marianne De Backer will participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on May 14. The event will be live webcasted and archived on the Vir website.